Tests to identify Immune based Cancer Treatment
Tumor mutation burden is a quantitative biomarker used to predict sensitivity to checkpoint inhibitor therapy in various solid tumor types reported to date. Early evidence suggests TMB is independent of PD-L1 expression, but TMB is correlated with higher response rate to checkpoint inhibitor. A minority of TMB-high tumors are also MSI-high. Tumor mutation load is associated with production of neoantigens which may be recognized by the immune system.
This immunohistochemical assay detects the level and expression sites of PD-L1 protein. As a companion or complementary diagnostic for certain tumors and indications, it helps identify patients for treatments including KEYTRUDA® (pembrolizumab), TECENTRIQ® (atezolizumab), OPDIVO® (nivolumab), IMFINZI™ (durvalumab)
This comprehensive test provides information an all 3 Immune Biomarkers.
BLOOD TEST FOR CANCER DETECTION, TREATMENT & MONITORING
Using 12 ml blood, this assays analyzes single nucleotide variants, short indels, copy number variations, and fusions that are frequently mutated in lung cancer
SCREENS 11 LUNG CANCER CAUSING GENES IN BLOOD
Genes: ALK, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, and TP53
Cell free DNA - EGFR Mutation Detection
(EGFR L858R, E746_A750del,& T790M)
Useful for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR T790M mutations
Cell free DNA (BRAF, NRAS, KRAS)
Cell free DNA - KRAS
Cell free DNA - BRAF
Cell free DNA - NRAS
BLOOD TEST FOR CANCER DETECTION, TREATMENT & MONITORING
Breast Cancer - Colon Cancer - Prostate Cancer
SINGLE TEST - BEFORE CHEMOTHERAPY
INCLUDES 2 TESTS
PRE- CHEMOTHERAPY AND
AFTER 1ST CYCLE OF CHEMOTHERAPY
INCLUDES 3 TESTS
PRE-CHEMOTHERAPY
AFTER 1ST CYCLE OF CHEMOTHERAPY &
AFTER 1 YEAR OF CHEMOTHERAPY COMPLETION
Clinical Grade Test to Detect Drugable Cancer Mutations
(DNA – RNA – Pharmacogenomics)
407 genes + TMB
Detection of cancer driver variants and assessment of tumor mutational burden (TMB), an emerging immuno-oncology biomarker, with next-generation sequencing
23 genes and 6 fusion transcripts (FDA IVD Approved)
Rearranged ALK, RET, ROS1 and the recently characterized NTRK1 genes play a key role in oncogenesis. This panel targets over 70 fusion transcripts in addition to major fusion gene families
52 genes, 26 copy Numbers
Multi-biomarker assay that enables you to target hotspots, SNVs, indels, CNVs, and gene fusions from DNA and RNA.
Screens BRCA-1 , BRCA-2 & 21 additional Genes responsible in
Breast and Ovarian Cancers
NGS - Liquid Biopsy - Molecular Tests
BLOOD TEST
SCREENS 12 LUNG CANCER CAUSING GENES IN BLOOD
Genes: ALK, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, and TP53
BLOOD TEST
Detects EGFR Mutation Detection
(EGFR L858R, E746_A750del,& T790M)
23 genes and 6 fusion transcripts
(FDA IVD Approved)
(DNA – RNA – Pharmacogenomics
(52 genes, 26 copy Numbers)
Detection & Enumeration - PFS/OS
EGFR BY ARMS PCR
ALK BY IHC
ROS1 BY FISH
MET BY FISH
EGFR BY RT PCR
ROS1 translocation by FISH &
ALK by IHC
NGS - Liquid Biopsy - Molecular Tests
(DNA – RNA – Pharmacogenomics)
Detection & Enumeration - PFS/OS
NGS - Liquid Biopsy - Molecular Tests
(DNA – RNA – Pharmacogenomics)
Detection & Enumeration - PFS/OS
Cell free DNA (BRAF, NRAS, KRAS)
Cell free DNA (BRAF)
Cell free DNA (NRAS)
Cell free DNA (KRAS)
NGS - Liquid Biopsy - Molecular Tests
(DNA – RNA – Pharmacogenomics)
Detection & Enumeration - PFS/OS
NGS - Liquid Biopsy - Molecular Tests
(DNA – RNA – Pharmacogenomics)
NGS - Liquid Biopsy - Molecular Tests
(DNA – RNA – Pharmacogenomics)
NGS - Liquid Biopsy - Molecular Tests
(DNA – RNA – Pharmacogenomics)
NPM1 mutation analysis
FLT3 mutation analysis
CEBPA mutation analysis
item[t(8;21),t(15;17),inv16,FLT3,NPM1]
[t(8;21),t(15;17),inv16]
QUALITATIVE BY RT-PCR
[t( 1;19) ,t(12 ;21), t (4;11),t(9; 22)]
Add a description about this item
Add a description about this item
Add a description about this item
(Molecular Analysis of Acquired Resistance to Imatinib)
Exon 14 mutation detection
To help you understand your risk of developing Cancer
Saliva-Blood Based Screening
Screens 143 genes for 25 hereditary cancers
Genetic Counseling Included
Saliva-Blood Based Screening
Screens 21 additional Genes for
Breast and Ovarian Cancers
Genetic Counseling Included
Saliva-Blood Based Screening
Screens for Breast and Ovarian Cancers
Genetic Counseling Included
Revalidation and Reconfirmation of Diagnosis
Tissue Biopsy is retested using >50 "Techniques and Lab Tests" to confirm Cancer Diagnosis
Tel: 9794048252
Monday - Friday: 9am - 5pm
Saturday: By appointment
Sunday: Closed